STAT+: With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
LONDON \u2014 The U.K.-based drugmaker GSK said early Wednesday that it planned to invest $30 billion in the U.S. over five years, an announcement timed to this week\u2019s state visit here by President Trump.<\/p>\n
The company, which said the funds would be used to expand research and manufacturing operations and build out AI capabilities, is the latest drugmaker to unveil major investments in the U.S. since the start of the Trump administration, following the likes of Eli Lilly<\/a>, AstraZeneca<\/a>, Novartis<\/a>, and others.\u00a0<\/p>\n The U.S. is the largest market for drugmakers, and the industry had been shifting more resources there even before Trump took office again. But the headline-grabbing sums have also allowed companies, under threat of tariffs on pharmaceutical products and of Trump\u2019s proposed drug pricing plan<\/a>, to appeal to the administration. On tariffs specifically, companies have argued they already make some drugs for U.S. patients in the U.S. \u2014 and also have committed to building up manufacturing there even further.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n